4-(pyrrolidin-1-yl)benzamide | 183557-79-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 4-(pyrrolidin-1-yl)benzamide
• 英文别名: 4-pyrrolidin-1-ylbenzamide
• CAS: 183557-79-1
• 化学式: C₁₁H₁₄N₂O
• mdl: MFCD09907634
• 分子量: 190.245
• InChiKey: SERASDFIHHDDRZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  46.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  methyl 8-(2-chloroacetyl)-dibenzo[b,d]furan-4-carboxylate 、 4-(pyrrolidin-1-yl)benzamide 在 tetraphosphorus decasulfide 作用下， 以 1,4-二氧六环 为溶剂， 反应 5.0h， 生成
  参考文献：
  名称：

  新型二苯并[ b，d ]呋喃羧酸作为潜在抗糖尿病药的合成与评价

  摘要：

  合成，表征和评估了一系列新颖的二苯并[ b，d ]呋喃单羧酸衍生物，以在体外抑制蛋白酪氨酸磷酸酶1B（PTP1B）的能力，以便将其用作潜在的抗糖尿病药。结构-活性关系研究导致鉴定出有效化合物5E，该化合物抑制PTP1B，IC 50值为82±0.43 nM。使用马来酸罗格列酮作为标准品，在体内筛选化合物5E作为抗糖尿病活性的候选药物。化合物5E结果显示，ob / ob小鼠的体重，摄食状态全血糖（WBG），禁食WBG，血浆葡萄糖和血浆胆固醇水平显着降低，而禁食血浆甘油三酸酯水平无明显降低。

  DOI：

  10.1016/j.ejmech.2010.05.020
• 作为产物：
  描述：

  4-(1-吡咯烷)苯甲腈 在 水 、 双氧水 、 sodium hydroxide 作用下， 以 乙醇 为溶剂， 以78%的产率得到4-(pyrrolidin-1-yl)benzamide
  参考文献：
  名称：

  新型二苯并[ b，d ]呋喃羧酸作为潜在抗糖尿病药的合成与评价

  摘要：

  合成，表征和评估了一系列新颖的二苯并[ b，d ]呋喃单羧酸衍生物，以在体外抑制蛋白酪氨酸磷酸酶1B（PTP1B）的能力，以便将其用作潜在的抗糖尿病药。结构-活性关系研究导致鉴定出有效化合物5E，该化合物抑制PTP1B，IC 50值为82±0.43 nM。使用马来酸罗格列酮作为标准品，在体内筛选化合物5E作为抗糖尿病活性的候选药物。化合物5E结果显示，ob / ob小鼠的体重，摄食状态全血糖（WBG），禁食WBG，血浆葡萄糖和血浆胆固醇水平显着降低，而禁食血浆甘油三酸酯水平无明显降低。

  DOI：

  10.1016/j.ejmech.2010.05.020

文献信息

• ALKYLQUINOLINE AND ALKYLQUINAZOLINE KINASE MODULATORS
  申请人：Baindur Nand

  公开号：US20060281772A1

  公开（公告）日：2006-12-14

  The invention is directed to alkylquinoline and alkylquinazoline compounds of Formula I: wherein R 1 , R 2 , R 3 , B, Z, G, Q and X are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of FLT3 and/or c-kit and/or TrkB, the use of such compounds to reduce or inhibit kinase activity of FLT3 and/or c-kit and/or TrkB in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to FLT3 and/or c-kit and/or TrkB. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.

  该发明涉及Formula I的烷基喹啉和烷基喹噁啉化合物： 其中R1、R2、R3、B、Z、G、Q和X如本文所定义，所述化合物的用途为蛋白酪氨酸激酶调节剂，特别是FLT3和/或c-kit和/或TrkB的抑制剂，所述化合物的用途为在细胞或受试者中减少或抑制FLT3和/或c-kit和/或TrkB的激酶活性，以及所述化合物的用途为预防或治疗受试者的细胞增殖紊乱和/或与FLT3和/或c-kit和/或TrkB相关的紊乱。本发明还涉及包括本发明化合物的药物组合物，以及治疗癌症和其他细胞增殖紊乱等疾病的方法。
• SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOPYRIMIDINES KINASE MODULATORS
  申请人：Baumann Andrew Christian

  公开号：US20060281755A1

  公开（公告）日：2006-12-14

  The invention is directed to a method of inhibiting FLT3 tyrosine kinase activity or expression or reducing FLT3 kinase activity or expression in a cell or a subject comprising the administration of a farnesyl transferase inhibitor and a FLT3 kinase inhibitor selected from aminopyrimidine compounds of Formula I′: where R 3 , B, Z, r and R 1 are as defined herein. Included within the present invention is both prophylactic and therapeutic methods for treating a subject at risk of (or susceptible to) developing a cell proliferative disorder or a disorder related to FLT3.

  这项发明涉及一种抑制FLT3酪氨酸激酶活性或表达或减少细胞或受试者中FLT3激酶活性或表达的方法，包括给予一种法尼基转移酶抑制剂和一种从式I′的氨基嘧啶化合物中选择的FLT3激酶抑制剂：其中R3、B、Z、r和R1如本文所定义。本发明涵盖了用于治疗处于发展细胞增殖障碍或与FLT3有关的障碍风险（或易感）的受试者的预防和治疗方法。
• Solid phase synthesis of aryl amines
  作者：Christopher A. Willoughby、Kevin T. Chapman

  DOI：10.1016/0040-4039(96)01633-4

  日期：1996.9

  A method for the solid phase synthesis of aryl amines is reported. The method involves a palladium mediated coupling reaction between aryl bromides and amines. The products are isolated in high purity and good yields. This method should prove to be a useful tool for constructing combinatorial libraries containing the aryl amine moiety.

  报道了一种固相合成芳基胺的方法。该方法涉及芳基溴化物和胺之间的钯介导的偶联反应。以高纯度和高收率分离出产物。该方法应被证明是用于构建包含芳基胺部分的组合文库的有用工具。
• Synergistic Modulation of Flt3 Kinase Using Alkylquinolines and Alkylquinazolines
  申请人：Baumann Andrew Christian

  公开号：US20070004660A1

  公开（公告）日：2007-01-04

  The invention is directed to a method of inhibiting FLT3 tyrosine kinase activity or expression or reducing FLT3 kinase activity or expression in a cell or a subject comprising the administration of a farnesyl transferase inhibitor and a FLT3 kinase inhibitor selected from alkylquinoline and alkylquinazoline compounds of Formula I′: where R 1 , R 2 , R 3 , Z, G, Q and X are as defined herein. Included within the present invention is both prophylactic and therapeutic methods for treating a subject at risk of (or susceptible to) developing a cell proliferative disorder or a disorder related to FLT3.

  本发明涉及一种抑制细胞或主体中FLT3酪氨酸激酶活性或表达或减少FLT3激酶活性或表达的方法，包括给予一种法尼酰转移酶抑制剂和一种从式I'的烷基喹啉和烷基喹唑啉化合物中选择的FLT3激酶抑制剂：其中R1、R2、R3、Z、G、Q和X如本文所定义。本发明包括治疗和预防方法，用于治疗或预防患有细胞增殖性疾病或与FLT3相关的疾病的患者。
• AMINOPYRIMIDINES AS KINASE MODULATORS
  申请人：Gaul David Michael

  公开号：US20070021435A1

  公开（公告）日：2007-01-25

  The invention is directed to aminopyrimidine compounds of Formula I: where R 3 , B, Z, r and R 1 are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of FLT3 and/or c-kit and/or TrkB, the use of such compounds to reduce or inhibit kinase activity of FLT3 and/or c-kit and/or TrkB in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to FLT3 and/or c-kit and/or TrkB. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.

  本发明涉及式I的氨基嘧啶化合物：其中R3、B、Z、r和R1的定义如本文所述，所述化合物的用途为蛋白酪氨酸激酶调节剂，特别是FLT3和/或c-kit和/或TrkB的抑制剂，所述化合物的用途为在细胞或受体中减少或抑制FLT3和/或c-kit和/或TrkB的激酶活性，并用于预防或治疗与FLT3和/或c-kit和/或TrkB相关的细胞增殖性疾病和/或疾病。本发明还涉及包含本发明化合物的药物组合物以及治疗癌症和其他细胞增殖性疾病的方法。